Neogenomics Inc reports results for the quarter ended June 30 - Earnings Summary

NeoGenomics

29/07/2025 14:31

Neogenomics Inc NEO.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of fifteen analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from zero cents to 6 cents per share.

Revenue rose 10.2% to $181.33 million from a year ago; analysts expected $182.69 million.

Neogenomics Inc's reported EPS for the quarter was a loss of 35 cents​.

The company reported a quarterly loss of $45.09 million.

Neogenomics Inc shares had fallen by 11.6% this quarter and lost 60.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 30.7% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Neogenomics Inc is $12.00, about 46.2% above its last closing price of $6.46

This summary was machine generated from LSEG data July 29 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
0.02
0.03
Beat
Mar. 31 2025
-0.01
0.00
Beat
Dec. 31 2024
0.03
0.04
Beat
Sep. 30 2024
0.01
0.05
Beat